<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trop Med Int Health</journal-id><journal-id journal-id-type="iso-abbrev">Trop. Med. Int. Health</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-3156</journal-id><journal-id journal-id-type="publisher-id">TMI</journal-id><journal-title-group><journal-title>Tropical Medicine &#x00026; International Health</journal-title></journal-title-group><issn pub-type="ppub">1360-2276</issn><issn pub-type="epub">1365-3156</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24655037</article-id><article-id pub-id-type="pmc">5396574</article-id><article-id pub-id-type="doi">10.1111/tmi.12304</article-id><article-id pub-id-type="publisher-id">TMI12304</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Hiv&#x00026;aids</subject></subj-group></article-categories><title-group><article-title>Adjusting the <styled-content style="fixed-case">HIV</styled-content> prevalence for non&#x02010;respondents using mortality rates in an open cohort in northwest Tanzania</article-title><alt-title alt-title-type="left-running-head">F. Tenu <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="tmi12304-cr-0001" contrib-type="author" corresp="yes"><name><surname>Tenu</surname><given-names>Filemon</given-names></name><xref ref-type="aff" rid="tmi12304-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="tmi12304-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="tmi12304-cr-0002" contrib-type="author"><name><surname>Isingo</surname><given-names>Raphael</given-names></name><xref ref-type="aff" rid="tmi12304-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="tmi12304-cr-0003" contrib-type="author"><name><surname>Zaba</surname><given-names>Basia</given-names></name><xref ref-type="aff" rid="tmi12304-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="tmi12304-cr-0004" contrib-type="author"><name><surname>Urassa</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="tmi12304-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="tmi12304-cr-0005" contrib-type="author"><name><surname>Todd</surname><given-names>Jim</given-names></name><xref ref-type="aff" rid="tmi12304-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="tmi12304-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="tmi12304-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="tmi12304-aff-0001"><label><sup>1</sup></label><institution>Amani Research Centre</institution><named-content content-type="city">Muheza</named-content><country country="TZ">Tanzania</country></aff><aff id="tmi12304-aff-0002"><label><sup>2</sup></label><institution>Kilimanjaro Christian Medical University College</institution><named-content content-type="city">Moshi</named-content><country country="TZ">Tanzania</country></aff><aff id="tmi12304-aff-0003"><label><sup>3</sup></label><institution>Mwanza Research Centre</institution><named-content content-type="city">Mwanza</named-content><country country="TZ">Tanzania</country></aff><aff id="tmi12304-aff-0004"><label><sup>4</sup></label><institution>London School of Hygiene and Tropical Medicine</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding Author Filemon Tenu</bold>, Amani Research Centre, P.O.Box 81, Muheza, Tanzania. E&#x02010;mail: <email>filemonitenu@yahoo.co.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>21</day><month>3</month><year>2014</year></pub-date><volume>19</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/tmi.2014.19.issue-6</issue-id><fpage>656</fpage><lpage>663</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2014 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2014 The Authors. <italic>Tropical Medicine &#x00026; International Health</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:TMI-19-656.pdf"/><abstract id="tmi12304-abs-0001"><title>Abstract</title><sec id="tmi12304-sec-0001"><title>Objective</title><p>To estimate <styled-content style="fixed-case">HIV</styled-content> prevalence in adults who have not tested for <styled-content style="fixed-case">HIV</styled-content> using age&#x02010;specific mortality rates and to adjust the overall population <styled-content style="fixed-case">HIV</styled-content> prevalence to include both tested and untested adults.</p></sec><sec id="tmi12304-sec-0002"><title>Methods</title><p>An open cohort study was established since 1994 with demographic surveillance system (<styled-content style="fixed-case">DSS</styled-content>) and five serological surveys conducted. Deaths from Kisesa <styled-content style="fixed-case">DSS</styled-content> were used to estimate mortality rates and 95% confidence intervals by <styled-content style="fixed-case">HIV</styled-content> status for 3&#x02010; 5&#x02010;year periods (1995&#x02013;1999, 2000&#x02013;2004, and 2005&#x02013;2009). Assuming that mortality rates in individuals who did not test for <styled-content style="fixed-case">HIV</styled-content> are similar to those in tested individuals, and dependent on age, sex and <styled-content style="fixed-case">HIV</styled-content> status and <styled-content style="fixed-case">HIV</styled-content>, prevalence was estimated.</p></sec><sec id="tmi12304-sec-0003"><title>Results</title><p>In 1995&#x02013;1999, mortality rates (per 1000 person years) were 43.7 (95% <styled-content style="fixed-case">CI</styled-content> 35.7&#x02013;53.4) for <styled-content style="fixed-case">HIV</styled-content> positive, 2.6 (95% <styled-content style="fixed-case">CI</styled-content> 2.1&#x02013;3.2) in <styled-content style="fixed-case">HIV</styled-content> negative and 16.4 (95% <styled-content style="fixed-case">CI</styled-content> 14.4&#x02013;18.7) in untested. In 2000&#x02013;2004, mortality rates were 43.3 (95% <styled-content style="fixed-case">CI</styled-content> 36.2&#x02013;51.9) in <styled-content style="fixed-case">HIV</styled-content> positive, 3.3 (95% <styled-content style="fixed-case">CI</styled-content> 2.8&#x02013;4.0) in <styled-content style="fixed-case">HIV</styled-content> negative and 11.9 (95% <styled-content style="fixed-case">CI</styled-content> 10.5&#x02013;13.6) in untested. In 2005&#x02013;2009, mortality rates were 30.7 (95% <styled-content style="fixed-case">CI</styled-content> 24.8&#x02013;38.0) in <styled-content style="fixed-case">HIV</styled-content> positive, 4.1 (95% <styled-content style="fixed-case">CI</styled-content> 3.5&#x02013;4.9) in <styled-content style="fixed-case">HIV</styled-content> negative and 5.7 (95% <styled-content style="fixed-case">CI</styled-content> 5.0&#x02013;6.6) in untested residents. In the three survey periods (1995&#x02013;1999, 2000&#x02013;2004, 2005&#x02013;2009), the adjusted period prevalences of <styled-content style="fixed-case">HIV</styled-content>, including the untested, were 13.5%, 11.6% and 7.1%, compared with the observed prevalence in the tested of 6.0%, 6.8 and 8.0%. The estimated prevalence in the untested was 33.4%, 21.6% and 6.1% in the three survey periods.</p></sec><sec id="tmi12304-sec-0004"><title>Conclusion</title><p>The simple model was able to estimate <styled-content style="fixed-case">HIV</styled-content> prevalence where a <styled-content style="fixed-case">DSS</styled-content> provided mortality data for untested residents.</p></sec></abstract><trans-abstract xml:lang="fr" abstract-type="main" id="tmi12304-abs-0101"><sec id="tmi12304-sec-0101" xml:lang="fr"><title>Objectif</title><p xml:lang="fr">Estimer la pr&#x000e9;valence du <styled-content style="fixed-case">VIH</styled-content> chez les adultes qui n'ont pas &#x000e9;t&#x000e9; test&#x000e9;s pour le <styled-content style="fixed-case">VIH</styled-content> en utilisant les taux de mortalit&#x000e9; par &#x000e2;ge et ajuster la pr&#x000e9;valence globale du <styled-content style="fixed-case">VIH</styled-content> dans la population incluant &#x000e0; la fois les adultes test&#x000e9;s et non test&#x000e9;s.</p></sec><sec id="tmi12304-sec-0102" xml:lang="fr"><title>M&#x000e9;thodes</title><p xml:lang="fr">Une &#x000e9;tude de cohorte ouverte a &#x000e9;t&#x000e9; &#x000e9;tablie depuis 1994 avec le syst&#x000e8;me de surveillance d&#x000e9;mographique (<styled-content style="fixed-case">SSD</styled-content>) et cinq enqu&#x000ea;tes s&#x000e9;rologiques ont &#x000e9;t&#x000e9; men&#x000e9;es. Les d&#x000e9;c&#x000e8;s dans le <styled-content style="fixed-case">SSD</styled-content> de Kisesa ont &#x000e9;t&#x000e9; utilis&#x000e9;s pour estimer les taux de mortalit&#x000e9; et les intervalles de confiance &#x000e0; 95% selon le statut <styled-content style="fixed-case">VIH</styled-content> pour trois p&#x000e9;riodes de cinq ans (1995&#x02010;1999, 2000&#x02010;2004, 2005&#x02010;2009). En supposant que les taux de mortalit&#x000e9; chez les personnes qui n'ont pas &#x000e9;t&#x000e9; test&#x000e9;s pour le <styled-content style="fixed-case">VIH</styled-content> soient semblables &#x000e0; ceux des personnes test&#x000e9;es, et d&#x000e9;pendent de l&#x02019;&#x000e2;ge, le sexe, le statut <styled-content style="fixed-case">VIH</styled-content> et le <styled-content style="fixed-case">VIH</styled-content>, la pr&#x000e9;valence a &#x000e9;t&#x000e9; estim&#x000e9;e.</p></sec><sec id="tmi12304-sec-0103" xml:lang="fr"><title>R&#x000e9;sultats</title><p xml:lang="fr">En 1995&#x02010;1999, les taux de mortalit&#x000e9; (pour 1000 personnes&#x02010;ann&#x000e9;es) &#x000e9;taient de 43,7 (<styled-content style="fixed-case">IC</styled-content>95%: 35,7 &#x02010; 53,4) chez les <styled-content style="fixed-case">VIH</styled-content> positifs, 2,6 (<styled-content style="fixed-case">IC</styled-content>95%: 2,1&#x02010;3,2) chez les s&#x000e9;ron&#x000e9;gatifs et 16,4 (<styled-content style="fixed-case">IC</styled-content>95%: 14,4 &#x02010; 18,7) chez les non test&#x000e9;s. En 2000&#x02010;2004, les taux de mortalit&#x000e9; &#x000e9;taient de 43,3 (<styled-content style="fixed-case">IC</styled-content>95%: 36,2 &#x02010; 51,9) chez les s&#x000e9;ropositifs, 3,3 (<styled-content style="fixed-case">IC</styled-content>95%: 2,8 &#x02010; 4,0) chez les s&#x000e9;ron&#x000e9;gatifs et 11,9 (<styled-content style="fixed-case">IC</styled-content>95%: 10,5 &#x02010; 13,6) chez les non test&#x000e9;s. En 2005&#x02010;2009, les taux de mortalit&#x000e9; &#x000e9;taient de 30,7 (<styled-content style="fixed-case">IC</styled-content>95%: 24,8 &#x02010; 38,0) chez s&#x000e9;ropositifs, 4,1 (<styled-content style="fixed-case">IC</styled-content>95%: 3,5&#x02010;4,9) chez les <styled-content style="fixed-case">VIH</styled-content> n&#x000e9;gatifs et 5,7 (<styled-content style="fixed-case">IC</styled-content>95%: 5,0 &#x000e0; 6,6) chez les non test&#x000e9;s. Au cours des trois p&#x000e9;riodes d'enqu&#x000ea;te (1995&#x02010;1999, 2000&#x02010;2004, 2005&#x02010;2009), les pr&#x000e9;valences ajust&#x000e9;s de la p&#x000e9;riode du <styled-content style="fixed-case">VIH</styled-content>, y compris les non test&#x000e9;s &#x000e9;taient de 13,5%; 11,6% et 7,1%, par rapport aux pr&#x000e9;valences observ&#x000e9;es dans l'essai qui &#x000e9;taient de 6,0%; 6,8% et 8,0%. La pr&#x000e9;valence estim&#x000e9;e chez les non test&#x000e9;s &#x000e9;tait de 33,4%, 21,6% et 6,1% dans les trois p&#x000e9;riodes de surveillance.</p></sec><sec id="tmi12304-sec-0104" xml:lang="fr"><title>Conclusion</title><p xml:lang="fr">Le mod&#x000e8;le simple a &#x000e9;t&#x000e9; en mesure d'estimer la pr&#x000e9;valence du <styled-content style="fixed-case">VIH</styled-content> dans un cadre o&#x000f9; un <styled-content style="fixed-case">SSD</styled-content> a fourni des donn&#x000e9;es de mortalit&#x000e9; pour les r&#x000e9;sidents non test&#x000e9;s.</p></sec></trans-abstract><trans-abstract xml:lang="es" abstract-type="main" id="tmi12304-abs-0102"><sec id="tmi12304-sec-0105" xml:lang="es"><title>Objetivo</title><p xml:lang="es">Calcular la prevalencia de <styled-content style="fixed-case">VIH</styled-content> en adultos que no se han hecho la prueba del <styled-content style="fixed-case">VIH</styled-content> utilizando tasas de mortalidad espec&#x000ed;ficas por edad, y ajustar la prevalencia total de <styled-content style="fixed-case">VIH</styled-content> en la poblaci&#x000f3;n para incluir tanto a adultos que se han realizado la prueba como a aquellos que no se la han hecho.</p></sec><sec id="tmi12304-sec-0106" xml:lang="es"><title>M&#x000e9;todos</title><p xml:lang="es">En 1994 se estableci&#x000f3; un estudio de cohortes abierto con sistema de vigilancia demogr&#x000e1;fica (<styled-content style="fixed-case">SVD</styled-content>) y desde entonces se han realizado cinco ensayos serol&#x000f3;gicos. Las muertes del <styled-content style="fixed-case">SVD</styled-content> de Kisesa se utilizaron para calcular las tasas de mortalidad e intervalos de confianza del 95% seg&#x000fa;n el estatus de <styled-content style="fixed-case">VIH</styled-content>, durante tres periodos de cinco a&#x000f1;os (1995&#x02010;1999, 2000&#x02010;2004, y 2005&#x02010;2009). Se calcul&#x000f3; la prevalencia de <styled-content style="fixed-case">VIH</styled-content> asumiendo que las tasas de mortalidad en individuos sin prueba del <styled-content style="fixed-case">VIH</styled-content> son similares a aquellos individuos que s&#x000ed; se han hecho la prueba, y dependientes de la edad, el sexo y el estatus de <styled-content style="fixed-case">VIH</styled-content>.</p></sec><sec id="tmi12304-sec-0107" xml:lang="es"><title>Resultados</title><p xml:lang="es">Entre 1995&#x02010;1999, las tasas de mortalidad (por 1,000 personas a&#x000f1;os) fueron de 43.7 (<styled-content style="fixed-case">IC</styled-content> 95% 35.7&#x02010;53.4) para <styled-content style="fixed-case">VIH</styled-content> positivos, 2.6 (<styled-content style="fixed-case">IC</styled-content> 95% 2.1&#x02010;3.2) en <styled-content style="fixed-case">VIH</styled-content> negativos y 16.4 (<styled-content style="fixed-case">IC</styled-content> 95% 14.4&#x02010;18.7) en sujetos sin prueba del <styled-content style="fixed-case">VIH</styled-content>. Entre el 2000&#x02010;2004, las tasas de mortalidad eran 43.3 (<styled-content style="fixed-case">IC</styled-content> 95% 36.2&#x02010;51.9) en <styled-content style="fixed-case">VIH</styled-content> positivos, 3.3 (<styled-content style="fixed-case">IC</styled-content> 95% 2.8&#x02010;4.0) en <styled-content style="fixed-case">VIH</styled-content> negativos y 11.9 (<styled-content style="fixed-case">IC</styled-content> 95% 10.5&#x02010;13.6) en sujetos sin prueba del <styled-content style="fixed-case">VIH</styled-content>. Entre el 2005&#x02010;2009, las tasas de mortalidad eran del 30.7 (<styled-content style="fixed-case">IC</styled-content> 95% 24.8&#x02010;38.0) en <styled-content style="fixed-case">VIH</styled-content> positivos, 4.1 (<styled-content style="fixed-case">IC</styled-content> 95% 3.5&#x02010;4.9) en <styled-content style="fixed-case">VIH</styled-content> negativos y 5.7 (<styled-content style="fixed-case">IC</styled-content> 95% 5.0&#x02010;6.6) en sujetos sin prueba del <styled-content style="fixed-case">VIH</styled-content>. Durante los tres periodos del estudio (1995&#x02010;1999, 2000&#x02010;2004, 2005&#x02010;2009), la prevalencia ajustada de <styled-content style="fixed-case">VIH</styled-content> para el periodo, incluyendo los sujetos sin prueba del <styled-content style="fixed-case">VIH</styled-content>, eran 13.5%, 11.6% y 7.1%, comparado con la prevalencia observada en la poblaci&#x000f3;n con una prueba de <styled-content style="fixed-case">VIH</styled-content> del 6.0%, 6.8 y 8.0%. La prevalencia calculada en los sujetos sin prueba fue del 33.4%, 21.6% y 6.1% en los tres periodos de estudio respectivamente.</p></sec><sec id="tmi12304-sec-0108" xml:lang="es"><title>Conclusi&#x000f3;n</title><p xml:lang="es">Un modelo simple ha permitido calcular la prevalencia de <styled-content style="fixed-case">VIH</styled-content> en donde los datos de mortalidad por <styled-content style="fixed-case">SVD</styled-content> aportaron datos de mortalidad para residentes sin prueba de <styled-content style="fixed-case">VIH</styled-content>.</p></sec></trans-abstract><kwd-group kwd-group-type="author-generated"><kwd id="tmi12304-kwd-0001">HIV</kwd><kwd id="tmi12304-kwd-0002">prevalence</kwd><kwd id="tmi12304-kwd-0003">estimation</kwd><kwd id="tmi12304-kwd-0004">model</kwd><kwd id="tmi12304-kwd-0005">untested</kwd><kwd id="tmi12304-kwd-0006">mortality</kwd></kwd-group><kwd-group kwd-group-type="author-generated"><kwd id="tmi12304-kwd-0101"><styled-content style="fixed-case">VIH</styled-content></kwd><kwd id="tmi12304-kwd-0102">pr&#x000e9;valence</kwd><kwd id="tmi12304-kwd-0103">estimation</kwd><kwd id="tmi12304-kwd-0104">mod&#x000e8;le</kwd><kwd id="tmi12304-kwd-0105">non test&#x000e9;</kwd><kwd id="tmi12304-kwd-0106">mortalit&#x000e9;</kwd></kwd-group><funding-group><award-group><funding-source>THRiVE Consortium</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Wellcome Trust</funding-source></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>tmi12304</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2014</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:19.04.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="tmi12304-ntgp-1101"><fn id="tmi12304-note-1101"><p>The copyright line for this article was changed on 01 February
2016 after original online publication.</p></fn></fn-group></notes></front><body><sec id="tmi12304-sec-0005"><title>Introduction</title><p>The number of people living with HIV worldwide in 2007 was estimated at 33.2 million, with subSaharan Africa (SSA) being the most affected region (WHO <xref rid="tmi12304-bib-0016" ref-type="ref">2008</xref>). Antenatal clinic (ANC) data obtained from pregnant women have been the main source of information for HIV prevalence trends and estimates of the number of people living with HIV (Garc&#x000ed;a&#x02010;Calleja <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0003" ref-type="ref">2006</xref>). The use of ANC data has several constraints such as under representation of remote rural populations, lack of data on men and non&#x02010;pregnant women and limited ability to assess risk factors of HIV (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0007" ref-type="ref">2006</xref>).</p><p>In recent years, trends and population estimates of HIV prevalence in SSA are also estimated from household surveys, surveys among high&#x02010;risk groups (Islam &#x00026; Conigrave <xref rid="tmi12304-bib-0004" ref-type="ref">2008</xref>) and population&#x02010;based surveys such as the demographic and health surveys (DHS) and AIDS indicator surveys (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0008" ref-type="ref">2008</xref>). The advantage of using population&#x02010;based surveys is that they provide reliable and nationally representative direct estimates of HIV prevalence in countries with generalised epidemics as well as understanding of the magnitude and spread of epidemics (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0008" ref-type="ref">2008</xref>). Another advantage of population&#x02010;based surveys is that they can be a source of direct data on the distribution of HIV infection among different adult populations, men, women (pregnant &#x00026; non&#x02010;pregnant) and across different geographical regions (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0007" ref-type="ref">2006</xref>).</p><p>The main challenge facing these surveys is a potential bias caused by non&#x02010;respondents which raises a major concern for analysis and generalisation (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>). The main reasons for non&#x02010;response in population&#x02010;based surveys are refusal to participate in HIV testing and absenteeism. Non&#x02010;response can bias population&#x02010;based estimates of HIV prevalence if it is systematically associated with HIV (Marston <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0005" ref-type="ref">2008</xref>; Floyd <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0002" ref-type="ref">2013</xref>). One method of overcoming the non&#x02010;response bias from population&#x02010;based surveys is using mortality rates to estimate HIV prevalence in non&#x02010;respondents (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>) and adjusting the overall HIV prevalence with a weighted average of the HIV prevalence in tested and untested residents.</p><p>This paper reports sex and age&#x02010;specific mortality rates in adults from a population cohort in north&#x02010;western Tanzania. The age&#x02010;specific mortality rates are used to adjust the population HIV prevalence for those who did not test for HIV.</p></sec><sec id="tmi12304-sec-0006"><title>Materials and methods</title><sec id="tmi12304-sec-0007"><title>Data source</title><p>This analysis employed data collected since 1994 from a demographic surveillance study (DSS) in Mwanza Region in northwest Tanzania, as described by Mwita (Mwita <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0010" ref-type="ref">2007</xref>).</p></sec><sec id="tmi12304-sec-0008"><title>Study design</title><p>An open cohort study was established in 1994, and the population was enumerated every 6&#x000a0;months. Vital registration data on births and deaths were obtained, and verbal autopsy interview was used to interpret cause of death. Five serological surveys have been carried&#x02010;out in 1994&#x02013;1995, 1997&#x02013;1998, 2000&#x02013;2001, 2003&#x02013;2004 and 2006&#x02013;2007. During these sero&#x02010;surveys, adults, aged 15&#x02013;54&#x000a0;years, were asked to provide blood samples for anonymous HIV testing and responded to questionnaires covering sexual behaviour, use of health services and attitudes towards HIV (Urassa <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0015" ref-type="ref">2001</xref>; Mwita <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0010" ref-type="ref">2007</xref>).</p></sec><sec id="tmi12304-sec-0009"><title>Definition of HIV status</title><p>HIV status was defined using data from all five HIV surveys between 1994 and 2007. Sero&#x02010;conversion date was obtained as the mid&#x02010;point between the last HIV negative test result and the first HIV positive test result. Residents were considered HIV negative from the date of their first HIV negative test until either the sero&#x02010;conversion date or 5&#x000a0;years after the last HIV negative test. Residents were considered HIV positive from the first HIV positive test or from the sero&#x02010;conversion date until 20&#x000a0;years after the last HIV positive test. Residents were considered of unknown HIV status prior to their first HIV test and for any period when they could not be defined as HIV positive or HIV negative according to the above definitions.</p></sec><sec id="tmi12304-sec-0010"><title>Calculation of mortality rates</title><p>Total person years of follow up (PYO) was calculated from 1st January 1995 or the day that the individual entered the cohort through immigration or on their 15th birthday. All residents were followed up until the date of death, out&#x02010;migration or on their 55th birthday. For residents who out&#x02010;migrated and then returned to the DSS, the time when they were out of the DSS was not included in the total PYO. Mortality rate was calculated as the quotient of total deaths and PYO. Age&#x02010;specific mortality rates were calculated for three 5&#x02010;year intervals: 1995&#x02013;1999, 2000&#x02013;2004 and 2005&#x02013;2009, these periods corresponding to a time of increasing HIV prevalence (1995&#x02013;1999; Mwaluko <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0009" ref-type="ref">2003</xref>), a time when HIV prevalence reached a plateau (Mwita <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0011" ref-type="ref">2008</xref>), and a time of antiretroviral therapy (ART) availability (Wringe <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0017" ref-type="ref">2012</xref>). Four age groups were used (15&#x02013;24&#x000a0;years, 25&#x02013;34&#x000a0;years, 35&#x02013;44&#x000a0;years and 45&#x02013;54&#x000a0;years), and for each period, mortality rates were calculated by age, sex and HIV status.</p></sec><sec id="tmi12304-sec-0011"><title>Principal analytical model</title><p>For those with unknown HIV status, the HIV prevalence was estimated as the weighted average of the mortality rate of those with known HIV serostatus (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>). The calculation of the HIV prevalence was obtained for each group of sex (<italic>s</italic>), age group (<italic>a</italic>) and time period (<italic>t</italic>), using the formula<disp-formula id="tmi12304-disp-0001"><label>(1)</label><mml:math id="nlm-math-1"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
</p><p>whereby, <italic>M</italic>
<sub><italic>u</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;mortality in the unknown HIV, <italic>M</italic>
<sub><italic>n</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;mortality in the known HIV &#x02212;ve, <italic>M</italic>
<sub><italic>p</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;mortality in the known HIV +ve, <italic>H</italic>
<sub><italic>u</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;Prevalence in the unknown HIV.</p><p>For those with known HIV status, the HIV prevalence in each age, sex and time period <italic>H</italic>
<sub><italic>k</italic></sub>(<italic>s,a,t</italic>) was estimated as the proportion of the person&#x02010;years lived by HIV positive persons, and was calculated as:<disp-formula id="tmi12304-disp-0002"><label>(2)</label><mml:math id="nlm-math-2"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
</p><p>whereby, <italic>Y</italic>
<sub><italic>p</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;Total person years lived by those tested positive, <italic>Y</italic>
<sub><italic>n</italic></sub>(<italic>s,a,t</italic>)&#x000a0;=&#x000a0;Total person years lived by those tested negative.</p><p>For each age, sex and period, the adjusted HIV prevalence (<italic>H</italic>
<sub><italic>w</italic></sub>(<italic>s,a,t</italic>)) was calculated as:<disp-formula id="tmi12304-disp-0003"><label>(3)</label><mml:math id="nlm-math-3"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
</p><p>From this, the overall adjusted HIV period prevalence for each sex aged 15&#x02013;54&#x000a0;years was obtained by multiplying the adjusted age prevalence of HIV by the proportion in each age band from a standardised population. To enable comparison between time periods, the standardised population was taken as the average from the Kisesa cohort across the whole time period 1995&#x02013;2009.</p></sec><sec id="tmi12304-sec-0012"><title>Ethical clearance</title><p>The research received ethical clearance from National Institute for Medical Research and approved by the Scientific and Ethical Review Committee of the National AIDS Control Programme of the Ministry of Health and Social Welfare, Tanzania. This work formed the dissertation project and was approved by the ethics review board at Kilimanjaro Christian Medical University College.</p></sec></sec><sec id="tmi12304-sec-0013"><title>Results</title><sec id="tmi12304-sec-0014"><title>Participation in HIV testing</title><p>Of eligible residents aged 15&#x02013;54&#x000a0;years, the participation rate was 72.3% (6566/9078) in 1994/95 and 54.7% (7171/13&#x000a0;110) in 2006/7. Participation rates were lower in males (58%) than females (67.5%) for all serological rounds (Table&#x000a0;<xref rid="tmi12304-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="tmi12304-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participation rate in <styled-content style="fixed-case">HIV</styled-content> testing among adults aged 15&#x02013;44&#x000a0;years of age</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Serology round</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Males</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Females</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Both sexes</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Tested</th><th align="left" valign="top" rowspan="1" colspan="1">Percent</th><th align="left" valign="top" rowspan="1" colspan="1">Tested</th><th align="left" valign="top" rowspan="1" colspan="1">Percent</th><th align="left" valign="top" rowspan="1" colspan="1">Tested</th><th align="left" valign="top" rowspan="1" colspan="1">Percent</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1994/1995</td><td align="left" char="." rowspan="1" colspan="1">3092</td><td align="left" char="." rowspan="1" colspan="1">70.2</td><td align="left" char="." rowspan="1" colspan="1">3474</td><td align="left" char="." rowspan="1" colspan="1">74.3</td><td align="left" char="." rowspan="1" colspan="1">6566</td><td align="left" char="." rowspan="1" colspan="1">72.3</td></tr><tr><td align="left" rowspan="1" colspan="1">1996/1997</td><td align="left" char="." rowspan="1" colspan="1">3337</td><td align="left" char="." rowspan="1" colspan="1">66.1</td><td align="left" char="." rowspan="1" colspan="1">4011</td><td align="left" char="." rowspan="1" colspan="1">74.0</td><td align="left" char="." rowspan="1" colspan="1">7348</td><td align="left" char="." rowspan="1" colspan="1">70.2</td></tr><tr><td align="left" rowspan="1" colspan="1">1999/2000</td><td align="left" char="." rowspan="1" colspan="1">2991</td><td align="left" char="." rowspan="1" colspan="1">55.4</td><td align="left" char="." rowspan="1" colspan="1">3992</td><td align="left" char="." rowspan="1" colspan="1">67.3</td><td align="left" char="." rowspan="1" colspan="1">6983</td><td align="left" char="." rowspan="1" colspan="1">61.6</td></tr><tr><td align="left" rowspan="1" colspan="1">2003/2004</td><td align="left" char="." rowspan="1" colspan="1">3585</td><td align="left" char="." rowspan="1" colspan="1">55.5</td><td align="left" char="." rowspan="1" colspan="1">4536</td><td align="left" char="." rowspan="1" colspan="1">64.2</td><td align="left" char="." rowspan="1" colspan="1">8121</td><td align="left" char="." rowspan="1" colspan="1">60.1</td></tr><tr><td align="left" rowspan="1" colspan="1">2006/2007</td><td align="left" char="." rowspan="1" colspan="1">2992</td><td align="left" char="." rowspan="1" colspan="1">47.7</td><td align="left" char="." rowspan="1" colspan="1">4179</td><td align="left" char="." rowspan="1" colspan="1">61.1</td><td align="left" char="." rowspan="1" colspan="1">7171</td><td align="left" char="." rowspan="1" colspan="1">54.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;997</td><td align="left" char="." rowspan="1" colspan="1">58.0</td><td align="left" char="." rowspan="1" colspan="1">20&#x000a0;192</td><td align="left" char="." rowspan="1" colspan="1">67.5</td><td align="left" char="." rowspan="1" colspan="1">36&#x000a0;189</td><td align="left" char="." rowspan="1" colspan="1">62.9</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="tmi12304-sec-0015"><title>Distribution of mortality rates by age, sex and HIV testing status</title><p>Among residents aged 15&#x02013;44&#x000a0;years of age, in the first 5&#x000a0;years of survey (1995&#x02013;1999), 320 deaths were observed in 44&#x000a0;359 PYO, while in 2000&#x02013;2004, 374 deaths were observed in 53&#x000a0;017 PYO, and in 2005&#x02013;2009, 313 deaths in 59&#x000a0;502 PYO (Table&#x000a0;<xref rid="tmi12304-tbl-0002" ref-type="table-wrap">2</xref>). In HIV negative females, mortality rates across the three periods remained similar, while in HIV negative males, an increased mortality rate (4.6 deaths per 1000 PYO) was observed in the final period (2005&#x02013;2009). HIV positive males and females had significantly higher mortality than HIV negatives, in all survey rounds (Figure&#x000a0;<xref rid="tmi12304-fig-0001" ref-type="fig">1</xref>). The overall mortality rate ratios (MRR) in females and males were between 13.6 and 19.4 for the first two periods (1995&#x02013;1999 and 2000&#x02013;2004). In the third period (2005&#x02013;2009), the MRR had dropped to 6.6 in males and 9.3 in females (Table&#x000a0;<xref rid="tmi12304-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="tmi12304-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Mortality rates and person years of follow up in <styled-content style="fixed-case">HIV</styled-content> negative and <styled-content style="fixed-case">HIV</styled-content> positive adults aged 15&#x02013;44&#x000a0;years from 1995 through 2009</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1"/><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HIV negative</th><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HIV positive</th><th align="left" rowspan="3" valign="top" colspan="1">MR ratio</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Deaths</th><th align="left" rowspan="2" valign="top" colspan="1">PY</th><th align="left" rowspan="2" valign="top" colspan="1">MR/1000</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">95% CI</th><th align="left" rowspan="2" valign="top" colspan="1">Deaths</th><th align="left" rowspan="2" valign="top" colspan="1">PY</th><th align="left" rowspan="2" valign="top" colspan="1">MR/1000</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">95% CI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" colspan="12" rowspan="1">1995&#x02013;1999 &#x02013; Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">16</td><td align="left" char="." rowspan="1" colspan="1">7681.8</td><td align="left" char="." rowspan="1" colspan="1">2.1</td><td align="left" char="." rowspan="1" colspan="1">1.3</td><td align="left" char="." rowspan="1" colspan="1">3.4</td><td align="left" char="." rowspan="1" colspan="1">1</td><td align="left" char="." rowspan="1" colspan="1">143.3</td><td align="left" char="." rowspan="1" colspan="1">7.0</td><td align="left" char="." rowspan="1" colspan="1">1.0</td><td align="left" char="." rowspan="1" colspan="1">49.5</td><td align="left" char="." rowspan="1" colspan="1">3.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">14</td><td align="left" char="." rowspan="1" colspan="1">4336.3</td><td align="left" char="." rowspan="1" colspan="1">3.2</td><td align="left" char="." rowspan="1" colspan="1">1.9</td><td align="left" char="." rowspan="1" colspan="1">5.5</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">369.6</td><td align="left" char="." rowspan="1" colspan="1">54.1</td><td align="left" char="." rowspan="1" colspan="1">34.9</td><td align="left" char="." rowspan="1" colspan="1">83.9</td><td align="left" char="." rowspan="1" colspan="1">16.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">12</td><td align="left" char="." rowspan="1" colspan="1">2850.5</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">2.4</td><td align="left" char="." rowspan="1" colspan="1">7.4</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">269.6</td><td align="left" char="." rowspan="1" colspan="1">74.2</td><td align="left" char="." rowspan="1" colspan="1">47.9</td><td align="left" char="." rowspan="1" colspan="1">110.0</td><td align="left" char="." rowspan="1" colspan="1">17.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">42</td><td align="left" char="." rowspan="1" colspan="1">14&#x000a0;868.7</td><td align="left" char="." rowspan="1" colspan="1">2.8</td><td align="left" char="." rowspan="1" colspan="1">2.1</td><td align="left" char="." rowspan="1" colspan="1">3.8</td><td align="left" char="." rowspan="1" colspan="1">41</td><td align="left" char="." rowspan="1" colspan="1">782.5</td><td align="left" char="." rowspan="1" colspan="1">52.4</td><td align="left" char="." rowspan="1" colspan="1">38.6</td><td align="left" char="." rowspan="1" colspan="1">71.2</td><td align="left" char="." rowspan="1" colspan="1">18.7</td></tr><tr><td align="left" colspan="12" rowspan="1">1995&#x02013;1999 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">13</td><td align="left" char="." rowspan="1" colspan="1">6649.7</td><td align="left" char="." rowspan="1" colspan="1">2.0</td><td align="left" char="." rowspan="1" colspan="1">1.1</td><td align="left" char="." rowspan="1" colspan="1">3.4</td><td align="left" char="." rowspan="1" colspan="1">6</td><td align="left" char="." rowspan="1" colspan="1">394.8</td><td align="left" char="." rowspan="1" colspan="1">15.2</td><td align="left" char="." rowspan="1" colspan="1">6.8</td><td align="left" char="." rowspan="1" colspan="1">33.8</td><td align="left" char="." rowspan="1" colspan="1">7.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">11</td><td align="left" char="." rowspan="1" colspan="1">5445.1</td><td align="left" char="." rowspan="1" colspan="1">2.0</td><td align="left" char="." rowspan="1" colspan="1">1.1</td><td align="left" char="." rowspan="1" colspan="1">3.6</td><td align="left" char="." rowspan="1" colspan="1">31</td><td align="left" char="." rowspan="1" colspan="1">596.6</td><td align="left" char="." rowspan="1" colspan="1">52.0</td><td align="left" char="." rowspan="1" colspan="1">36.5</td><td align="left" char="." rowspan="1" colspan="1">73.9</td><td align="left" char="." rowspan="1" colspan="1">26.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">13</td><td align="left" char="." rowspan="1" colspan="1">3563.0</td><td align="left" char="." rowspan="1" colspan="1">3.6</td><td align="left" char="." rowspan="1" colspan="1">2.1</td><td align="left" char="." rowspan="1" colspan="1">6.3</td><td align="left" char="." rowspan="1" colspan="1">11</td><td align="left" char="." rowspan="1" colspan="1">229.8</td><td align="left" char="." rowspan="1" colspan="1">47.9</td><td align="left" char="." rowspan="1" colspan="1">26.5</td><td align="left" char="." rowspan="1" colspan="1">86.4</td><td align="left" char="." rowspan="1" colspan="1">13.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">37</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;657.7</td><td align="left" char="." rowspan="1" colspan="1">2.4</td><td align="left" char="." rowspan="1" colspan="1">1.7</td><td align="left" char="." rowspan="1" colspan="1">3.3</td><td align="left" char="." rowspan="1" colspan="1">48</td><td align="left" char="." rowspan="1" colspan="1">1221.2</td><td align="left" char="." rowspan="1" colspan="1">39.3</td><td align="left" char="." rowspan="1" colspan="1">29.6</td><td align="left" char="." rowspan="1" colspan="1">52.2</td><td align="left" char="." rowspan="1" colspan="1">16.4</td></tr><tr><td align="left" colspan="12" rowspan="1">2000&#x02013;2004 &#x02013; Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">8</td><td align="left" char="." rowspan="1" colspan="1">7983.1</td><td align="left" char="." rowspan="1" colspan="1">1.0</td><td align="left" char="." rowspan="1" colspan="1">0.5</td><td align="left" char="." rowspan="1" colspan="1">2.0</td><td align="left" char="." rowspan="1" colspan="1">3</td><td align="left" char="." rowspan="1" colspan="1">236.3</td><td align="left" char="." rowspan="1" colspan="1">12.7</td><td align="left" char="." rowspan="1" colspan="1">4.1</td><td align="left" char="." rowspan="1" colspan="1">39.4</td><td align="left" char="." rowspan="1" colspan="1">12.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">9</td><td align="left" char="." rowspan="1" colspan="1">4442.9</td><td align="left" char="." rowspan="1" colspan="1">2.0</td><td align="left" char="." rowspan="1" colspan="1">1.1</td><td align="left" char="." rowspan="1" colspan="1">3.9</td><td align="left" char="." rowspan="1" colspan="1">16</td><td align="left" char="." rowspan="1" colspan="1">365.9</td><td align="left" char="." rowspan="1" colspan="1">43.7</td><td align="left" char="." rowspan="1" colspan="1">26.8</td><td align="left" char="." rowspan="1" colspan="1">71.4</td><td align="left" char="." rowspan="1" colspan="1">21.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">16</td><td align="left" char="." rowspan="1" colspan="1">3128.1</td><td align="left" char="." rowspan="1" colspan="1">5.1</td><td align="left" char="." rowspan="1" colspan="1">3.1</td><td align="left" char="." rowspan="1" colspan="1">8.3</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" char="." rowspan="1" colspan="1">328.4</td><td align="left" char="." rowspan="1" colspan="1">57.9</td><td align="left" char="." rowspan="1" colspan="1">36.9</td><td align="left" char="." rowspan="1" colspan="1">90.7</td><td align="left" char="." rowspan="1" colspan="1">11.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">33</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;554.1</td><td align="left" char="." rowspan="1" colspan="1">2.1</td><td align="left" char="." rowspan="1" colspan="1">1.5</td><td align="left" char="." rowspan="1" colspan="1">3.0</td><td align="left" char="." rowspan="1" colspan="1">38</td><td align="left" char="." rowspan="1" colspan="1">930.6</td><td align="left" char="." rowspan="1" colspan="1">40.8</td><td align="left" char="." rowspan="1" colspan="1">29.7</td><td align="left" char="." rowspan="1" colspan="1">56.1</td><td align="left" char="." rowspan="1" colspan="1">19.4</td></tr><tr><td align="left" colspan="12" rowspan="1">2000&#x02013;2004 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">12</td><td align="left" char="." rowspan="1" colspan="1">6965.3</td><td align="left" char="." rowspan="1" colspan="1">1.7</td><td align="left" char="." rowspan="1" colspan="1">1.0</td><td align="left" char="." rowspan="1" colspan="1">3.0</td><td align="left" char="." rowspan="1" colspan="1">8</td><td align="left" char="." rowspan="1" colspan="1">409.7</td><td align="left" char="." rowspan="1" colspan="1">19.5</td><td align="left" char="." rowspan="1" colspan="1">9.8</td><td align="left" char="." rowspan="1" colspan="1">39.0</td><td align="left" char="." rowspan="1" colspan="1">11.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">14</td><td align="left" char="." rowspan="1" colspan="1">5813.8</td><td align="left" char="." rowspan="1" colspan="1">2.4</td><td align="left" char="." rowspan="1" colspan="1">1.4</td><td align="left" char="." rowspan="1" colspan="1">4.1</td><td align="left" char="." rowspan="1" colspan="1">28</td><td align="left" char="." rowspan="1" colspan="1">691.3</td><td align="left" char="." rowspan="1" colspan="1">40.5</td><td align="left" char="." rowspan="1" colspan="1">28.0</td><td align="left" char="." rowspan="1" colspan="1">58.7</td><td align="left" char="." rowspan="1" colspan="1">16.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">23</td><td align="left" char="." rowspan="1" colspan="1">4427.6</td><td align="left" char="." rowspan="1" colspan="1">5.2</td><td align="left" char="." rowspan="1" colspan="1">3.5</td><td align="left" char="." rowspan="1" colspan="1">7.8</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">367.8</td><td align="left" char="." rowspan="1" colspan="1">54.4</td><td align="left" char="." rowspan="1" colspan="1">35.1</td><td align="left" char="." rowspan="1" colspan="1">84.3</td><td align="left" char="." rowspan="1" colspan="1">10.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">49</td><td align="left" char="." rowspan="1" colspan="1">17&#x000a0;206.8</td><td align="left" char="." rowspan="1" colspan="1">2.8</td><td align="left" char="." rowspan="1" colspan="1">2.2</td><td align="left" char="." rowspan="1" colspan="1">3.8</td><td align="left" char="." rowspan="1" colspan="1">56</td><td align="left" char="." rowspan="1" colspan="1">1468.8</td><td align="left" char="." rowspan="1" colspan="1">38.1</td><td align="left" char="." rowspan="1" colspan="1">29.3</td><td align="left" char="." rowspan="1" colspan="1">49.5</td><td align="left" char="." rowspan="1" colspan="1">13.6</td></tr><tr><td align="left" colspan="12" rowspan="1">2005&#x02013;2009 &#x02013; Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" char="." rowspan="1" colspan="1">7119.7</td><td align="left" char="." rowspan="1" colspan="1">2.7</td><td align="left" char="." rowspan="1" colspan="1">1.7</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">1</td><td align="left" char="." rowspan="1" colspan="1">212.0</td><td align="left" char="." rowspan="1" colspan="1">4.7</td><td align="left" char="." rowspan="1" colspan="1">0.7</td><td align="left" char="." rowspan="1" colspan="1">33.5</td><td align="left" char="." rowspan="1" colspan="1">1.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">14</td><td align="left" char="." rowspan="1" colspan="1">3289.6</td><td align="left" char="." rowspan="1" colspan="1">4.3</td><td align="left" char="." rowspan="1" colspan="1">2.5</td><td align="left" char="." rowspan="1" colspan="1">7.2</td><td align="left" char="." rowspan="1" colspan="1">14</td><td align="left" char="." rowspan="1" colspan="1">288.5</td><td align="left" char="." rowspan="1" colspan="1">48.5</td><td align="left" char="." rowspan="1" colspan="1">28.7</td><td align="left" char="." rowspan="1" colspan="1">81.9</td><td align="left" char="." rowspan="1" colspan="1">11.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">26</td><td align="left" char="." rowspan="1" colspan="1">2461.1</td><td align="left" char="." rowspan="1" colspan="1">10.6</td><td align="left" char="." rowspan="1" colspan="1">7.2</td><td align="left" char="." rowspan="1" colspan="1">15.5</td><td align="left" char="." rowspan="1" colspan="1">10</td><td align="left" char="." rowspan="1" colspan="1">325.2</td><td align="left" char="." rowspan="1" colspan="1">30.7</td><td align="left" char="." rowspan="1" colspan="1">16.5</td><td align="left" char="." rowspan="1" colspan="1">57.1</td><td align="left" char="." rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">59</td><td align="left" char="." rowspan="1" colspan="1">12&#x000a0;870.4</td><td align="left" char="." rowspan="1" colspan="1">4.6</td><td align="left" char="." rowspan="1" colspan="1">3.6</td><td align="left" char="." rowspan="1" colspan="1">5.9</td><td align="left" char="." rowspan="1" colspan="1">25</td><td align="left" char="." rowspan="1" colspan="1">825.7</td><td align="left" char="." rowspan="1" colspan="1">30.3</td><td align="left" char="." rowspan="1" colspan="1">20.5</td><td align="left" char="." rowspan="1" colspan="1">44.8</td><td align="left" char="." rowspan="1" colspan="1">6.6</td></tr><tr><td align="left" colspan="12" rowspan="1">2005&#x02013;2009 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">6</td><td align="left" char="." rowspan="1" colspan="1">5777.4</td><td align="left" char="." rowspan="1" colspan="1">1.0</td><td align="left" char="." rowspan="1" colspan="1">0.5</td><td align="left" char="." rowspan="1" colspan="1">2.3</td><td align="left" char="." rowspan="1" colspan="1">4</td><td align="left" char="." rowspan="1" colspan="1">314.0</td><td align="left" char="." rowspan="1" colspan="1">12.7</td><td align="left" char="." rowspan="1" colspan="1">4.8</td><td align="left" char="." rowspan="1" colspan="1">33.9</td><td align="left" char="." rowspan="1" colspan="1">12.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">15</td><td align="left" char="." rowspan="1" colspan="1">4806.4</td><td align="left" char="." rowspan="1" colspan="1">3.1</td><td align="left" char="." rowspan="1" colspan="1">1.9</td><td align="left" char="." rowspan="1" colspan="1">5.2</td><td align="left" char="." rowspan="1" colspan="1">14</td><td align="left" char="." rowspan="1" colspan="1">636.7</td><td align="left" char="." rowspan="1" colspan="1">22.0</td><td align="left" char="." rowspan="1" colspan="1">13.0</td><td align="left" char="." rowspan="1" colspan="1">37.1</td><td align="left" char="." rowspan="1" colspan="1">7.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" char="." rowspan="1" colspan="1">3903.3</td><td align="left" char="." rowspan="1" colspan="1">4.9</td><td align="left" char="." rowspan="1" colspan="1">3.1</td><td align="left" char="." rowspan="1" colspan="1">7.6</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">509.0</td><td align="left" char="." rowspan="1" colspan="1">39.3</td><td align="left" char="." rowspan="1" colspan="1">25.4</td><td align="left" char="." rowspan="1" colspan="1">60.9</td><td align="left" char="." rowspan="1" colspan="1">8.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">40</td><td align="left" char="." rowspan="1" colspan="1">14&#x000a0;487.1</td><td align="left" char="." rowspan="1" colspan="1">2.8</td><td align="left" char="." rowspan="1" colspan="1">2.0</td><td align="left" char="." rowspan="1" colspan="1">3.8</td><td align="left" char="." rowspan="1" colspan="1">38</td><td align="left" char="." rowspan="1" colspan="1">1459.6</td><td align="left" char="." rowspan="1" colspan="1">26.0</td><td align="left" char="." rowspan="1" colspan="1">18.9</td><td align="left" char="." rowspan="1" colspan="1">35.8</td><td align="left" char="." rowspan="1" colspan="1">9.3</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="tmi12304-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Trends of mortality rates in three survey periods.</p></caption><graphic id="nlm-graphic-1" xlink:href="TMI-19-656-g001"/></fig><p>In the first two periods (1995&#x02013;1999 and 2000&#x02013;2004) for both males and females, the overall mortality for untested residents was 2&#x02013;2.5 times as high as those who had tested for HIV (Table&#x000a0;<xref rid="tmi12304-tbl-0003" ref-type="table-wrap">3</xref>). In the last 5&#x000a0;years of survey 2005&#x02013;2009, the mortality rates for tested and untested individuals were lower than previous years of survey. In the final period (2005&#x02013;2009), the mortality rates in untested residents were similar to those in residents who had tested for HIV (Table&#x000a0;<xref rid="tmi12304-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="tmi12304-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Mortality rates and person years of follow up in adults aged 15&#x02013;44&#x000a0;years, who tested for <styled-content style="fixed-case">HIV</styled-content>, and who did not test for <styled-content style="fixed-case">HIV</styled-content>, from 1995 through 2009</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1"/><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Did not test</th><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Tested</th><th align="left" rowspan="3" valign="top" colspan="1">MR ratio</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Deaths</th><th align="left" rowspan="2" valign="top" colspan="1">PY</th><th align="left" rowspan="2" valign="top" colspan="1">MR/1000</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">95% CI</th><th align="left" rowspan="2" valign="top" colspan="1">Deaths</th><th align="left" rowspan="2" valign="top" colspan="1">PY</th><th align="left" rowspan="2" valign="top" colspan="1">MR/1000</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">95% CI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" colspan="12" rowspan="1">1995&#x02013;1999 &#x02013; Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">17</td><td align="left" char="." rowspan="1" colspan="1">2650.0</td><td align="left" char="." rowspan="1" colspan="1">6.4</td><td align="left" char="." rowspan="1" colspan="1">4.0</td><td align="left" char="." rowspan="1" colspan="1">10.3</td><td align="left" char="." rowspan="1" colspan="1">17</td><td align="left" char="." rowspan="1" colspan="1">7825.1</td><td align="left" char="." rowspan="1" colspan="1">2.2</td><td align="left" char="." rowspan="1" colspan="1">1.4</td><td align="left" char="." rowspan="1" colspan="1">3.5</td><td align="left" char="." rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">32</td><td align="left" char="." rowspan="1" colspan="1">2117.2</td><td align="left" char="." rowspan="1" colspan="1">15.1</td><td align="left" char="." rowspan="1" colspan="1">10.7</td><td align="left" char="." rowspan="1" colspan="1">21.4</td><td align="left" char="." rowspan="1" colspan="1">34</td><td align="left" char="." rowspan="1" colspan="1">4705.9</td><td align="left" char="." rowspan="1" colspan="1">7.2</td><td align="left" char="." rowspan="1" colspan="1">5.2</td><td align="left" char="." rowspan="1" colspan="1">10.1</td><td align="left" char="." rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">30</td><td align="left" char="." rowspan="1" colspan="1">1287.6</td><td align="left" char="." rowspan="1" colspan="1">23.3</td><td align="left" char="." rowspan="1" colspan="1">16.3</td><td align="left" char="." rowspan="1" colspan="1">33.3</td><td align="left" char="." rowspan="1" colspan="1">32</td><td align="left" char="." rowspan="1" colspan="1">3120.1</td><td align="left" char="." rowspan="1" colspan="1">10.3</td><td align="left" char="." rowspan="1" colspan="1">7.3</td><td align="left" char="." rowspan="1" colspan="1">14.5</td><td align="left" char="." rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">79</td><td align="left" char="." rowspan="1" colspan="1">6054.8</td><td align="left" char="." rowspan="1" colspan="1">13.0</td><td align="left" char="." rowspan="1" colspan="1">10.5</td><td align="left" char="." rowspan="1" colspan="1">16.3</td><td align="left" char="." rowspan="1" colspan="1">83</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;651.2</td><td align="left" char="." rowspan="1" colspan="1">5.3</td><td align="left" char="." rowspan="1" colspan="1">4.3</td><td align="left" char="." rowspan="1" colspan="1">6.6</td><td align="left" char="." rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" colspan="12" rowspan="1">1995&#x02013;1999 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">24</td><td align="left" char="." rowspan="1" colspan="1">3434.6</td><td align="left" char="." rowspan="1" colspan="1">7.0</td><td align="left" char="." rowspan="1" colspan="1">4.7</td><td align="left" char="." rowspan="1" colspan="1">10.4</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" char="." rowspan="1" colspan="1">7044.5</td><td align="left" char="." rowspan="1" colspan="1">2.7</td><td align="left" char="." rowspan="1" colspan="1">1.7</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">31</td><td align="left" char="." rowspan="1" colspan="1">1655.9</td><td align="left" char="." rowspan="1" colspan="1">18.7</td><td align="left" char="." rowspan="1" colspan="1">13.2</td><td align="left" char="." rowspan="1" colspan="1">26.6</td><td align="left" char="." rowspan="1" colspan="1">42</td><td align="left" char="." rowspan="1" colspan="1">6041.7</td><td align="left" char="." rowspan="1" colspan="1">7.0</td><td align="left" char="." rowspan="1" colspan="1">5.1</td><td align="left" char="." rowspan="1" colspan="1">9.4</td><td align="left" char="." rowspan="1" colspan="1">2.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">18</td><td align="left" char="." rowspan="1" colspan="1">683.9</td><td align="left" char="." rowspan="1" colspan="1">26.3</td><td align="left" char="." rowspan="1" colspan="1">16.6</td><td align="left" char="." rowspan="1" colspan="1">41.8</td><td align="left" char="." rowspan="1" colspan="1">24</td><td align="left" char="." rowspan="1" colspan="1">3792.8</td><td align="left" char="." rowspan="1" colspan="1">6.3</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">9.4</td><td align="left" char="." rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">73</td><td align="left" char="." rowspan="1" colspan="1">5774.4</td><td align="left" char="." rowspan="1" colspan="1">12.6</td><td align="left" char="." rowspan="1" colspan="1">10.1</td><td align="left" char="." rowspan="1" colspan="1">15.9</td><td align="left" char="." rowspan="1" colspan="1">85</td><td align="left" char="." rowspan="1" colspan="1">16&#x000a0;878.9</td><td align="left" char="." rowspan="1" colspan="1">5.0</td><td align="left" char="." rowspan="1" colspan="1">4.1</td><td align="left" char="." rowspan="1" colspan="1">6.2</td><td align="left" char="." rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" colspan="12" rowspan="1">2000&#x02013;2004 &#x02013; Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">24</td><td align="left" char="." rowspan="1" colspan="1">3931.7</td><td align="left" char="." rowspan="1" colspan="1">6.1</td><td align="left" char="." rowspan="1" colspan="1">4.1</td><td align="left" char="." rowspan="1" colspan="1">9.1</td><td align="left" char="." rowspan="1" colspan="1">11</td><td align="left" char="." rowspan="1" colspan="1">8219.3</td><td align="left" char="." rowspan="1" colspan="1">1.3</td><td align="left" char="." rowspan="1" colspan="1">0.7</td><td align="left" char="." rowspan="1" colspan="1">2.4</td><td align="left" char="." rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">35</td><td align="left" char="." rowspan="1" colspan="1">3364.9</td><td align="left" char="." rowspan="1" colspan="1">10.4</td><td align="left" char="." rowspan="1" colspan="1">7.5</td><td align="left" char="." rowspan="1" colspan="1">14.5</td><td align="left" char="." rowspan="1" colspan="1">25</td><td align="left" char="." rowspan="1" colspan="1">4808.8</td><td align="left" char="." rowspan="1" colspan="1">5.2</td><td align="left" char="." rowspan="1" colspan="1">3.5</td><td align="left" char="." rowspan="1" colspan="1">7.7</td><td align="left" char="." rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">46</td><td align="left" char="." rowspan="1" colspan="1">2123.6</td><td align="left" char="." rowspan="1" colspan="1">21.7</td><td align="left" char="." rowspan="1" colspan="1">16.2</td><td align="left" char="." rowspan="1" colspan="1">28.9</td><td align="left" char="." rowspan="1" colspan="1">35</td><td align="left" char="." rowspan="1" colspan="1">3456.5</td><td align="left" char="." rowspan="1" colspan="1">10.1</td><td align="left" char="." rowspan="1" colspan="1">7.3</td><td align="left" char="." rowspan="1" colspan="1">14.1</td><td align="left" char="." rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">105</td><td align="left" char="." rowspan="1" colspan="1">9420.2</td><td align="left" char="." rowspan="1" colspan="1">11.1</td><td align="left" char="." rowspan="1" colspan="1">9.2</td><td align="left" char="." rowspan="1" colspan="1">13.5</td><td align="left" char="." rowspan="1" colspan="1">71</td><td align="left" char="." rowspan="1" colspan="1">16&#x000a0;484.7</td><td align="left" char="." rowspan="1" colspan="1">4.3</td><td align="left" char="." rowspan="1" colspan="1">3.4</td><td align="left" char="." rowspan="1" colspan="1">5.4</td><td align="left" char="." rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" colspan="12" rowspan="1">2000&#x02013;2004 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">24</td><td align="left" char="." rowspan="1" colspan="1">4883.2</td><td align="left" char="." rowspan="1" colspan="1">4.9</td><td align="left" char="." rowspan="1" colspan="1">3.3</td><td align="left" char="." rowspan="1" colspan="1">7.3</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">7375.0</td><td align="left" char="." rowspan="1" colspan="1">2.7</td><td align="left" char="." rowspan="1" colspan="1">1.7</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">43</td><td align="left" char="." rowspan="1" colspan="1">2557.0</td><td align="left" char="." rowspan="1" colspan="1">16.8</td><td align="left" char="." rowspan="1" colspan="1">12.5</td><td align="left" char="." rowspan="1" colspan="1">22.7</td><td align="left" char="." rowspan="1" colspan="1">42</td><td align="left" char="." rowspan="1" colspan="1">6505.1</td><td align="left" char="." rowspan="1" colspan="1">6.5</td><td align="left" char="." rowspan="1" colspan="1">4.8</td><td align="left" char="." rowspan="1" colspan="1">8.7</td><td align="left" char="." rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">26</td><td align="left" char="." rowspan="1" colspan="1">995.8</td><td align="left" char="." rowspan="1" colspan="1">26.1</td><td align="left" char="." rowspan="1" colspan="1">17.8</td><td align="left" char="." rowspan="1" colspan="1">38.3</td><td align="left" char="." rowspan="1" colspan="1">43</td><td align="left" char="." rowspan="1" colspan="1">4795.4</td><td align="left" char="." rowspan="1" colspan="1">9.0</td><td align="left" char="." rowspan="1" colspan="1">6.7</td><td align="left" char="." rowspan="1" colspan="1">12.1</td><td align="left" char="." rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">93</td><td align="left" char="." rowspan="1" colspan="1">8436.0</td><td align="left" char="." rowspan="1" colspan="1">11.0</td><td align="left" char="." rowspan="1" colspan="1">9.0</td><td align="left" char="." rowspan="1" colspan="1">13.5</td><td align="left" char="." rowspan="1" colspan="1">105</td><td align="left" char="." rowspan="1" colspan="1">18&#x000a0;675.6</td><td align="left" char="." rowspan="1" colspan="1">5.6</td><td align="left" char="." rowspan="1" colspan="1">4.6</td><td align="left" char="." rowspan="1" colspan="1">6.8</td><td align="left" char="." rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" colspan="12" rowspan="1">2005&#x02013;2009 <italic>&#x02013;</italic> Males</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">16</td><td align="left" char="." rowspan="1" colspan="1">6244.6</td><td align="left" char="." rowspan="1" colspan="1">2.6</td><td align="left" char="." rowspan="1" colspan="1">1.6</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">20</td><td align="left" char="." rowspan="1" colspan="1">7331.7</td><td align="left" char="." rowspan="1" colspan="1">2.7</td><td align="left" char="." rowspan="1" colspan="1">1.8</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">33</td><td align="left" char="." rowspan="1" colspan="1">5594.8</td><td align="left" char="." rowspan="1" colspan="1">5.9</td><td align="left" char="." rowspan="1" colspan="1">4.2</td><td align="left" char="." rowspan="1" colspan="1">8.3</td><td align="left" char="." rowspan="1" colspan="1">28</td><td align="left" char="." rowspan="1" colspan="1">3578.1</td><td align="left" char="." rowspan="1" colspan="1">7.8</td><td align="left" char="." rowspan="1" colspan="1">5.4</td><td align="left" char="." rowspan="1" colspan="1">11.3</td><td align="left" char="." rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">32</td><td align="left" char="." rowspan="1" colspan="1">3489.0</td><td align="left" char="." rowspan="1" colspan="1">9.2</td><td align="left" char="." rowspan="1" colspan="1">6.5</td><td align="left" char="." rowspan="1" colspan="1">13.0</td><td align="left" char="." rowspan="1" colspan="1">36</td><td align="left" char="." rowspan="1" colspan="1">2786.3</td><td align="left" char="." rowspan="1" colspan="1">12.9</td><td align="left" char="." rowspan="1" colspan="1">9.3</td><td align="left" char="." rowspan="1" colspan="1">17.9</td><td align="left" char="." rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">81</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;328.5</td><td align="left" char="." rowspan="1" colspan="1">5.3</td><td align="left" char="." rowspan="1" colspan="1">4.3</td><td align="left" char="." rowspan="1" colspan="1">6.6</td><td align="left" char="." rowspan="1" colspan="1">84</td><td align="left" char="." rowspan="1" colspan="1">13&#x000a0;696.2</td><td align="left" char="." rowspan="1" colspan="1">6.1</td><td align="left" char="." rowspan="1" colspan="1">5.0</td><td align="left" char="." rowspan="1" colspan="1">7.6</td><td align="left" char="." rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" colspan="12" rowspan="1">2005&#x02013;2009 &#x02013; Females</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">15&#x02013;24</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" char="." rowspan="1" colspan="1">7687.7</td><td align="left" char="." rowspan="1" colspan="1">2.5</td><td align="left" char="." rowspan="1" colspan="1">1.6</td><td align="left" char="." rowspan="1" colspan="1">3.9</td><td align="left" char="." rowspan="1" colspan="1">10</td><td align="left" char="." rowspan="1" colspan="1">6091.4</td><td align="left" char="." rowspan="1" colspan="1">1.6</td><td align="left" char="." rowspan="1" colspan="1">0.9</td><td align="left" char="." rowspan="1" colspan="1">3.1</td><td align="left" char="." rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" char="." rowspan="1" colspan="1">29</td><td align="left" char="." rowspan="1" colspan="1">4666.3</td><td align="left" char="." rowspan="1" colspan="1">6.2</td><td align="left" char="." rowspan="1" colspan="1">4.3</td><td align="left" char="." rowspan="1" colspan="1">8.9</td><td align="left" char="." rowspan="1" colspan="1">29</td><td align="left" char="." rowspan="1" colspan="1">5443.1</td><td align="left" char="." rowspan="1" colspan="1">5.3</td><td align="left" char="." rowspan="1" colspan="1">3.7</td><td align="left" char="." rowspan="1" colspan="1">7.7</td><td align="left" char="." rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" char="." rowspan="1" colspan="1">22</td><td align="left" char="." rowspan="1" colspan="1">2176.6</td><td align="left" char="." rowspan="1" colspan="1">10.1</td><td align="left" char="." rowspan="1" colspan="1">6.7</td><td align="left" char="." rowspan="1" colspan="1">15.4</td><td align="left" char="." rowspan="1" colspan="1">39</td><td align="left" char="." rowspan="1" colspan="1">4412.2</td><td align="left" char="." rowspan="1" colspan="1">8.8</td><td align="left" char="." rowspan="1" colspan="1">6.5</td><td align="left" char="." rowspan="1" colspan="1">12.1</td><td align="left" char="." rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" char="." rowspan="1" colspan="1">70</td><td align="left" char="." rowspan="1" colspan="1">14&#x000a0;530.5</td><td align="left" char="." rowspan="1" colspan="1">4.8</td><td align="left" char="." rowspan="1" colspan="1">3.8</td><td align="left" char="." rowspan="1" colspan="1">6.1</td><td align="left" char="." rowspan="1" colspan="1">78</td><td align="left" char="." rowspan="1" colspan="1">15&#x000a0;946.7</td><td align="left" char="." rowspan="1" colspan="1">4.9</td><td align="left" char="." rowspan="1" colspan="1">3.9</td><td align="left" char="." rowspan="1" colspan="1">6.1</td><td align="left" char="." rowspan="1" colspan="1">1.0</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="tmi12304-sec-0016"><title>Adjusted HIV prevalence</title><p>Estimating the period prevalence of HIV from the mortality rates showed that HIV prevalence for adults who did not test for HIV in 1995&#x02013;1999 was significantly higher across all age groups and sex. A total of 30&#x000a0;527 person&#x02010;years were contributed by adults who tested negative; and 2004 person years were contributed by HIV positive individuals, giving an observed period prevalence of 6.2% for tested residents in 1995&#x02013;1999. The mortality for HIV negative individuals was 2.6 deaths per 1000 PYO, 44.4 deaths per 1000 PYO for HIV positive individuals and 12.8 deaths per 1000 PYO for individuals who did not test for HIV, giving a period prevalence of 24.5% for residents who did not test in 1995&#x02013;1999. Taking into account the period prevalence of HIV and person years for HIV negative, HIV positive and untested individuals (11&#x000a0;829 PYO), the overall period prevalence of HIV adjusted for the whole population was 11.1% in the period of 1995&#x02013;1999.</p><p>In the period of 2000&#x02013;2004, a total of 32&#x000a0;761 person years of follow up were recorded among HIV negatives, 2399 person years for HIV positives and 17&#x000a0;856 PYO for the untested, making an overall period prevalence of 6.8% for those who tested for HIV. The mortality rates (death per 1000 PYO) for HIV negatives, HIV positives and untested were 2.5, 39.2 and 11.1, respectively, giving a period prevalence of 23.4% for the untested. The adjusted period prevalence of HIV for the whole population was 12.4% in this survey period (Figure&#x000a0;<xref rid="tmi12304-fig-0002" ref-type="fig">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="tmi12304-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Period Prevalence of <styled-content style="fixed-case">HIV</styled-content> by age and sex from 1995 to 2009.</p></caption><graphic id="nlm-graphic-3" xlink:href="TMI-19-656-g002"/></fig><p>Individuals who tested negative for HIV in the time period of 2005&#x02013;2009 were followed up for 27&#x000a0;357 PYO; HIV positives were followed up for 2285 PYO and untested for 29&#x000a0;859 PYO, making a period prevalence of 7.7% for the tested individuals. Using the overall mortality rates of 3.6 deaths per 1000 PYO for the HIV negative individuals, 27.6 deaths per 1000 PYO for HIV positive and 5.1 deaths per 1000 PYO for untested individuals, the estimated period prevalence of HIV for the untested residents was 6.0%. The weighted period prevalence of HIV for the tested and untested individuals was 6.9% in this time interval for adults aged 15&#x02013;44&#x000a0;years (Figure&#x000a0;<xref rid="tmi12304-fig-0002" ref-type="fig">2</xref>).</p></sec></sec><sec id="tmi12304-sec-0017"><title>Discussion</title><p>Many studies conducted in subSaharan Africa (Garc&#x000ed;a&#x02010;Calleja <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0003" ref-type="ref">2006</xref>; Marston <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0005" ref-type="ref">2008</xref>; Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>) have found poor participation in HIV testing particularly among males, giving rise to potential bias in the estimated HIV prevalence. We used the observed deaths and person years contributed by the residents in Kisesa DSS to adjust the HIV prevalence for the whole population in Kisesa. Based on the observed mortality, our analysis showed, in the period from 1995 to 2004, residents who did not test for HIV had significantly higher period prevalence of HIV than residents who tested for HIV across both sexes and all age groups. We calculated weighted period prevalence of HIV for the whole population and found that the weighted HIV prevalence was 80% higher than the observed HIV prevalence in both 1995&#x02013;1999 and 2000&#x02013;2005. However, for the period 2005&#x02013;2009, we did not find increased mortality among those who had not tested for HIV, and the weighted HIV prevalence was 10% lower than that observed in those that tested for HIV in the surveys.</p><p>In this analysis, the proportion of non&#x02010;respondents increased in each subsequent serological survey, with a non&#x02010;participation rate of 28% in the first sero&#x02013;survey and increased to 45% in the last sero&#x02010;survey. These findings are similar to rural South Africa (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>) and Malawi (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0008" ref-type="ref">2008</xref>). Several surveys mentioned reasons for not consenting for HIV testing as absenteeism (Marston <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0005" ref-type="ref">2008</xref>; Reniers &#x00026; Eaton <xref rid="tmi12304-bib-0014" ref-type="ref">2009</xref>) and knowing that one is HIV positive already is less likely to participate, which may lead to underestimation of HIV prevalence (Floyd <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0002" ref-type="ref">2013</xref>).</p><p>We investigated the pattern of mortality from 1995 to 2009 and found that mortality rates among HIV negative residents did not change much over the 15&#x000a0;years period. However, the mortality for HIV&#x02010;positive and untested decreased in each subsequent survey round. Although the mortality rate for HIV&#x02010;negative residents did not change significantly with time, mortality rates for HIV&#x02010;positive residents were 17 times higher than that of HIV&#x02010;negative residents in 1995&#x02013;1999, 13 times higher than HIV negatives in 2000&#x02013;2005 and eight times higher in 2005&#x02013;2009 survey rounds. This was similar to the findings from South Africa, where the mortality rate for those who tested positive was 11&#x02013;19 times higher than mortality in HIV&#x02010;negative individuals (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0012" ref-type="ref">2007</xref>). HIV&#x02010;positive males had slightly higher mortality rates than females in all survey years and mortality increased with age for both males and females. The proportion of Kisesa residents who die between the age of 15&#x000a0;years and 60&#x000a0;years was 49% and 46% for men and women, respectively, and attributed this increase of mortality to AIDS epidemic (Urassa <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0015" ref-type="ref">2001</xref>). There has been a significant decrease of mortality for all residents in Kisesa cohort Michael <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0006" ref-type="ref">2014</xref>). The decrease of mortality among HIV&#x02010;positive residents may be explained by the introduction of ART and better control and treatment of opportunistic infections.</p><p>Using DHS data from prior to the advent of ART in 14 African countries, including Tanzania, Mishra showed that untested males and females had significantly higher predicted prevalence of HIV than tested individuals (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0008" ref-type="ref">2008</xref>). Mishra did not use our model; instead, they used regression model to predict HIV prevalence among non&#x02010;testers using several indicators including, age, education, wealth index, residence, marital status, religion and geographic region. This study adapted the model that was previously applied to longitudinal data in KwaZulu&#x02010;Natal in South Africa by Nyirenda <italic>et&#x000a0;al</italic>. (<xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>). We had similar findings to Nyirenda in the periods up to 2005, with HIV prevalence in all age groups higher in those who had not tested for HIV compared with those who had tested. However, in the period between 2005 and 2009, when ART became available to the population, there was little difference in the mortality rates and the estimated HIV prevalence between those who had tested for HIV and those who had not tested for HIV.</p><p>This analysis makes the assumption that among those who test and those who do not test, the mortality rates for HIV positive subjects are the same, and the mortality rates for HIV negative subjects are the same. In the final period of analysis (2005&#x02013;2009), when ART became available in Tanzania, as expected, the mortality rates in those who did not test was higher than the mortality rates in the HIV negatives and lower than the mortality rates in the HIV positives. However, unlike in the previous periods, the estimated period prevalence of HIV in the untested was lower than the HIV prevalence in the tested. This could have been because some of those who did not take the anonymous test for HIV in our survey had previously tested HIV positive and because they knew their HIV status had been able to access ART, and thereby had improved survival over those who did test for HIV in our surveys. With the advent of ART, the mortality rates of HIV positive people who test and the mortality rates of HIV positive people who do not test differ, and the assumption behind this adjustment to the observed HIV prevalence does not hold.</p><p>In the first two periods, this model showed that if we do not take into account HIV prevalence in the un&#x02010;tested individuals, HIV prevalence estimated from individuals who consented to HIV testing can be underestimated. Similar findings have been documented from the analysis of eight DHS and one AIDS Indicator Survey in African countries (Marston <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0005" ref-type="ref">2008</xref>). However, with the advent of ART, the relationship between HIV testing and mortality has changed, and the methods used in the analysis may not be useful to obtain an adjusted HIV prevalence in the population.</p><p>This model did not use detailed demographic data such as mobility, occupation, alcohol use, number of sexual partners, marital status, age at first sex, religion or any complex mathematical computations. It only used mortality and HIV testing status to estimate HIV prevalence for non&#x02010;respondents. The model has been commended by Nyirenda <italic>et&#x000a0;al</italic>. in South Africa (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>) to be used in DSS settings across Africa, but this may not be suitable with the advent of ART. Other models used to estimate HIV prevalence for non&#x02010;testers such as multiple imputations (Barnighausen <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0001" ref-type="ref">2008</xref>) and regression equations (Mishra <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0008" ref-type="ref">2008</xref>) use detailed demographic characteristics which may suffer from reporting bias. In addition to that, detailed demographic characteristics are not uniformly collected in many DSS as compared to mortality data so relying on demographic data can lead to biased estimates (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>). One advantage of the mortality model is that it can be used whenever there is prospective mortality follow&#x02010;up data for individuals who participated in sero&#x02010;survey and those who did not participate even if there was only one sero&#x02010;survey conducted (Nyirenda <italic>et&#x000a0;al</italic>. <xref rid="tmi12304-bib-0013" ref-type="ref">2010</xref>). Moreover, researchers who opt to use this model do not need advanced mathematical expertise instead they just need to know simple arithmetic calculations to apply the model.</p><p>This model cannot be applied to the data from cross&#x02010;sectional studies where point prevalence is used as a measure of disease frequency. The model needs prospective adult mortality data for the calculation of the period prevalence of HIV in a specified population at risk that have the disease of interest over a specified period of time. Many national estimates of HIV prevalence uses data from cross&#x02010;sectional surveys which cannot be accommodated by this model (Islam &#x00026; Conigrave <xref rid="tmi12304-bib-0004" ref-type="ref">2008</xref>).</p></sec><sec id="tmi12304-sec-0018"><title>Conclusion</title><p>This study has found poor participation in HIV testing among residents in Kisesa ward particularly among males, and the proportion of residents testing maintained gradual decrease for each subsequent year of sero&#x02010;survey. Mortality for non&#x02010;respondents was significantly higher than HIV&#x02010;negative residents. Moreover, mortality increased with age of residents and was slightly higher among untested males than untested females. HIV prevalence for non&#x02010;respondents was significantly higher in 1994&#x02013;2004 survey years than prevalence of tested residents, and may provide an accurate adjustment for the calculation of the population HIV prevalence. However, with the advent of ART, this model may not allow an accurate adjustment for the population HIV prevalence.</p></sec></body><back><ack id="tmi12304-sec-0019"><title>Acknowledgements</title><p>The authors acknowledge the sponsorship for MSc programme received from THRiVE Consortium and contributions from Jane Rogathe, Tolbert Sonda and Rija Abeid of Kilimanjaro Christian Medical Centre.</p></ack><ref-list content-type="cited-references" id="tmi12304-bibl-0001"><title>References</title><ref id="tmi12304-bib-0001"><mixed-citation publication-type="journal" id="tmi12304-cit-0001">
<string-name>
<surname>Barnighausen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tanser</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gqwede</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Mbizana</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Herbst</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Newell</surname>
<given-names>ML</given-names>
</string-name> (<year>2008</year>) <article-title>High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population&#x02010;based study</article-title>. <source>AIDS</source>
<volume>22</volume>(<issue>1</issue>), <fpage>139</fpage>&#x02013;<lpage>144</lpage>.<pub-id pub-id-type="pmid">18090402</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0002"><mixed-citation publication-type="journal" id="tmi12304-cit-0002">
<string-name>
<surname>Floyd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Molesworth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>A</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2013</year>) <article-title>Underestimation of HIV prevalence in surveys when some people already know their status, and ways to reduce the bias</article-title>. <source>AIDS</source>
<volume>27</volume>(<issue>2</issue>) <fpage>233</fpage>&#x02013;<lpage>242</lpage>.<pub-id pub-id-type="pmid">22842993</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0003"><mixed-citation publication-type="journal" id="tmi12304-cit-0003">
<string-name>
<surname>Garc&#x000ed;a&#x02010;Calleja</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Gouws</surname>
<given-names>E</given-names>
</string-name> &#x00026; <string-name>
<surname>Ghys</surname>
<given-names>PD</given-names>
</string-name> (<year>2006</year>) <article-title>National population based HIV prevalence surveys in sub&#x02010;Saharan Africa: results and implications for HIV and AIDS estimates</article-title>. <source>Sexually Transmitted Infections</source>
<volume>82</volume> (<issue>Suppl. 3</issue>), <fpage>iii64</fpage>&#x02013;<lpage>iii70</lpage>.<pub-id pub-id-type="pmid">16735296</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0004"><mixed-citation publication-type="journal" id="tmi12304-cit-0004">
<string-name>
<surname>Islam</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Conigrave</surname>
<given-names>KM</given-names>
</string-name> (<year>2008</year>) <article-title>REVIEW HIV and sexual risk behaviors among recognized high&#x02010;risk groups in Bangladesh: need for a comprehensive prevention program</article-title>. <source>International Journal of Infectious Diseases</source>
<volume>12</volume>, <fpage>363</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">18325810</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0005"><mixed-citation publication-type="journal" id="tmi12304-cit-0005">
<string-name>
<surname>Marston</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Harriss</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Slaymaker</surname>
<given-names>E</given-names>
</string-name> (<year>2008</year>) <article-title>Non&#x02010;response bias in estimates of HIV prevalence due to the mobility of absentees in national population&#x02010;based surveys: a study of nine national surveys</article-title>. <source>Sexually Transmitted Infections</source>
<volume>84</volume> (<issue>Suppl. I</issue>), <fpage>71</fpage>&#x02013;<lpage>78</lpage>.</mixed-citation></ref><ref id="tmi12304-bib-0006"><mixed-citation publication-type="journal" id="tmi12304-cit-0006">
<string-name>
<surname>Michael</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kanjala</surname>
<given-names>C</given-names>
</string-name> &#x00026; <string-name>
<surname>Calvert</surname>
<given-names>C</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2014</year>) <article-title>Does the Spectrum model accurately predict trends in adult mortality? Evaluation of model estimates using empirical data from a rural HIV community cohort study in north&#x02010;western Tanzania</article-title>. <source>Global Health Action</source>
<volume>7</volume>, <fpage>21783</fpage>.<pub-id pub-id-type="pmid">24438873</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0007"><mixed-citation publication-type="journal" id="tmi12304-cit-0007">
<string-name>
<surname>Mishra</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vaessen</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Boerma</surname>
<given-names>JT</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2006</year>) <article-title>HIV testing in national population&#x02010;based surveys : experience from the Demographic and Health Surveys</article-title>. <source>Bulletin of the World Health Organization</source>
<volume>84</volume>(<issue>7</issue>), <fpage>537</fpage>&#x02013;<lpage>545</lpage>.<pub-id pub-id-type="pmid">16878227</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0008"><mixed-citation publication-type="journal" id="tmi12304-cit-0008">
<string-name>
<surname>Mishra</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Barrere</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>R</given-names>
</string-name> &#x00026; <string-name>
<surname>Khan</surname>
<given-names>S</given-names>
</string-name> (<year>2008</year>) <article-title>Evaluation of bias in HIV seroprevalence estimates from national household surveys</article-title>. <source>Sexually Transmitted Infections</source>
<volume>84</volume> (<issue>Suppl. I</issue>), <fpage>i63</fpage>&#x02013;<lpage>i70</lpage>.<pub-id pub-id-type="pmid">18647869</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0009"><mixed-citation publication-type="journal" id="tmi12304-cit-0009">
<string-name>
<surname>Mwaluko</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Urassa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Isingo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zaba</surname>
<given-names>B</given-names>
</string-name> &#x00026; <string-name>
<surname>Boerma</surname>
<given-names>JT</given-names>
</string-name> (<year>2003</year>) <article-title>Trends in HIV and sexual behaviour in a longitudinal study in a rural population in Tanzania, 1994&#x02010;2000</article-title>. <source>AIDS</source>
<volume>17</volume>(<issue>18</issue>), <fpage>2645</fpage>&#x02013;<lpage>2651</lpage>.<pub-id pub-id-type="pmid">14685059</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0010"><mixed-citation publication-type="journal" id="tmi12304-cit-0010">
<string-name>
<surname>Wambura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Urassa</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Isingo</surname>
<given-names>R</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2007</year>) <article-title>HIV prevalence and incidence in rural Tanzania results from 10&#x000a0;years of follow&#x02010;up in an open&#x02010;cohort study</article-title>. <source>Journal of acquired immune deficiency syndromes</source>
<volume>46</volume>(<issue>5</issue>), <fpage>616</fpage>&#x02013;<lpage>623</lpage>.<pub-id pub-id-type="pmid">18043316</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0011"><mixed-citation publication-type="journal" id="tmi12304-cit-0011">
<string-name>
<surname>Mwita</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chilongani</surname>
<given-names>J</given-names>
</string-name> &#x00026; <string-name>
<surname>White</surname>
<given-names>R</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2008</year>) <article-title>Has the HIV epidemic in rural Mwanza, Tanzania reached a plateau?</article-title>
<source>Tanzania Journal of Health Research</source>
<volume>10</volume>(<issue>3</issue>), <fpage>117</fpage>&#x02013;<lpage>123</lpage>.<pub-id pub-id-type="pmid">19024335</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0012"><mixed-citation publication-type="journal" id="tmi12304-cit-0012">
<string-name>
<surname>Nyirenda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hosegood</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>B&#x000e4;rnighausen</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Newell</surname>
<given-names>ML</given-names>
</string-name> (<year>2007</year>) <article-title>Mortality levels and trends by HIV serostatus in rural South Africa</article-title>. <source>AIDS</source>
<volume>21</volume> (<issue>Suppl. 6</issue>), <fpage>S73</fpage>&#x02013;<lpage>S79</lpage>.</mixed-citation></ref><ref id="tmi12304-bib-0013"><mixed-citation publication-type="journal" id="tmi12304-cit-0013">
<string-name>
<surname>Nyirenda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zaba</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>B&#x000e4;rnighausen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hosegood</surname>
<given-names>V</given-names>
</string-name> &#x00026; <string-name>
<surname>Newell</surname>
<given-names>ML</given-names>
</string-name> (<year>2010</year>) <article-title>Adjusting HIV prevalence for survey non&#x02010;response using mortality rates: an application of the method using surveillance data from Rural South Africa</article-title>. <source>PLoS ONE</source>
<volume>5</volume>(<issue>8</issue>), <fpage>e12370</fpage>.<pub-id pub-id-type="pmid">20811499</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0014"><mixed-citation publication-type="journal" id="tmi12304-cit-0014">
<string-name>
<surname>Reniers</surname>
<given-names>G</given-names>
</string-name> &#x00026; <string-name>
<surname>Eaton</surname>
<given-names>J</given-names>
</string-name> (<year>2009</year>) <article-title>Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys</article-title>. <source>AIDS</source>
<volume>23</volume>(<issue>5</issue>), <fpage>621</fpage>&#x02013;<lpage>629</lpage>.<pub-id pub-id-type="pmid">19182677</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0015"><mixed-citation publication-type="journal" id="tmi12304-cit-0015">
<string-name>
<surname>Urassa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boerma</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Isingo</surname>
<given-names>R</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2001</year>) <article-title>The impact of HIV/AIDS on mortality and household mobility in rural Tanzania</article-title>. <source>AIDS</source>
<volume>15</volume>(<issue>15</issue>), <fpage>2017</fpage>&#x02013;<lpage>2023</lpage>.<pub-id pub-id-type="pmid">11600831</pub-id></mixed-citation></ref><ref id="tmi12304-bib-0016"><mixed-citation publication-type="miscellaneous" id="tmi12304-cit-0016">
<collab collab-type="authors">WHO</collab>
(<year>2008</year>) <article-title>World health statistics 2008</article-title>. World Health Organization. Downloaded from <ext-link ext-link-type="uri" xlink:href="http://www.who.int/whosis/whostat/">http://www.who.int/whosis/whostat/</ext-link>.</mixed-citation></ref><ref id="tmi12304-bib-0017"><mixed-citation publication-type="journal" id="tmi12304-cit-0017">
<string-name>
<surname>Wringe</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Floyd</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Kazooba</surname>
<given-names>P</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2012</year>) <article-title>Antiretroviral therapy uptake and coverage in four HIV community cohort studies in sub&#x02010;Saharan Africa</article-title>. <source>Tropical Medicine &#x00026; International Health</source>
<volume>17</volume>(<issue>8</issue>), <fpage>e38</fpage>&#x02013;<lpage>e48</lpage>.<pub-id pub-id-type="pmid">22943378</pub-id></mixed-citation></ref></ref-list></back></article>